On a personal have recovered the price of the house I had to give my ex wife last year on a clean break settlement. :) We are derisked. Even if we fund a phase1 on aurora ourselves we have more cash coming in than we can spend for the next 2 years. Getting to licence on chk1 is 62% chance not the industry norm of 5%. I can repost the link if needed. Multiple trials increases the chances os some not failing. Chk1 may give me an annual income equal to my investment in 5 years. Aurora+flt3 is next most advanced. There is no cure for cancer. But for some types of leukaemia we appeared to cure it in mice. If we can design a trial that shows early efficacy it's a $4bn compound. So I feel derisked even if the sp wiggles. But the big comfort is the lack of institutional investors. The guys making a killing are the researched among us who run valuations. There are no decent analyst coverage. No institutional investors. In 6 months we have moved to being a clinical company. And signed our first revenue generating deal. Prornai has 11 institutional investors who now know us. Stephen Parker deals with 7 institutional investors as chairman at sln. They will be coming on board. They can now value our assets and income stream. They can't buy via a placing as we don't need cash. So next 6 months will see buy orders being worked in the background as our investment grade goes up. Sit back and relax for 6 months whilst we get a gradual rise of institutions. With spikes on news licences or a takeover. Good luck all sensible folks.
I don't think waiting is an issue. Believe in the science, as Pronai recently have. Tyk2 the only orally taken candidate out there due to the patents we own from the smallest compound required to build the kinase inhibitors, went into pre clinical trials 25th July, on four different fronts. Janssen, licenced a tyk2 inhibitor from Carna Bio last year, and on August 5th this year terminated it, citing strategic positions. The Tyk2 helps in rheumatism arthritis, psoriasis and the like. Check out Janssen and what they do. Prior to the herd arriving on Tuesday, this board was full of concise information, but those on here prior Monday will know we were awaiting news on a few fronts. It's only my opinion, but we may not see any news until a further licence deal or perhaps a buyout if Janssen want that patent regarding Tyk2. So those of us who have gleaned this board for sometime greater than a fortnight, I say to you, hold onto those shares, buy if you can comfortably. Let's get excited about lack of news :) Love peace and harmony.
or you can say 5 years later sareum is still here and has not folded.... or 5 years on, they have licenced 1 molecule out, have done a development deal on another molecule and a collaboration on another one,,
Been here in 2011. Decided to bail. Got burnt quite a bit. Even now...5 years later it is sitting at 1.2p. I remember the good old days of 3-4p spike. These days with licensing deals it is 1.2p. Ask yourself why? Because the market is now aware that absolute results / outcome is still a bit to go. That too if it does work. I'm not deramping. Trust me, been here ...some of SAR's income was from me. I just think it will be a tad longer...no less than a year before any concrete news that will even allow this sp to reach the heights of 2011. It is sad but unfortunately true.
here, i am not sure how to value the drug they have developed or yada yada yada...but considering we are in no need for placings for a while now, and progress is awaited on multiple lines now, plus the sale royalties, although lets be honest we will not get them for a while should still boost the sp, as the market tries to revalue the company .lot of ii might buy in just because of that potential here
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.